BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pleguezuelos O, James E, Fernandez A, Lopes V, Rosas LA, Cervantes-Medina A, Cleath J, Edwards K, Neitzey D, Gu W, Hunsberger S, Taubenberger JK, Stoloff G, Memoli MJ. Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. NPJ Vaccines 2020;5:22. [PMID: 32194999 DOI: 10.1038/s41541-020-0174-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Ura T, Takeuchi M, Kawagoe T, Mizuki N, Okuda K, Shimada M. Current Vaccine Platforms in Enhancing T-Cell Response. Vaccines (Basel) 2022;10:1367. [PMID: 36016254 DOI: 10.3390/vaccines10081367] [Reference Citation Analysis]
2 Wang WC, Sayedahmed EE, Sambhara S, Mittal SK. Progress towards the Development of a Universal Influenza Vaccine. Viruses 2022;14:1684. [PMID: 36016306 DOI: 10.3390/v14081684] [Reference Citation Analysis]
3 Oh J, Subbiah J, Kim KH, Park BR, Bhatnagar N, Garcia KR, Liu R, Jung YJ, Shin CH, Seong BL, Kang SM. Impact of hemagglutination activity and M2e immunity on conferring protection against influenza viruses. Virology 2022;574:37-46. [PMID: 35914365 DOI: 10.1016/j.virol.2022.07.010] [Reference Citation Analysis]
4 Park J, Fong Legaspi SL, Schwartzman LM, Gygli SM, Sheng Z, Freeman AD, Matthews LM, Xiao Y, Ramuta MD, Batchenkova NA, Qi L, Rosas LA, Williams SL, Scherler K, Gouzoulis M, Bellayr I, Morens DM, Walters K, Memoli MJ, Kash JC, Taubenberger JK. An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets. Sci Transl Med 2022;14:eabo2167. [DOI: 10.1126/scitranslmed.abo2167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang Y, Wang Y, Jia C, Li G, Zhang W, Li Q, Chen X, Leng W, Huang L, Xie Z, Zhang H, You W, An R, Jiang H, Zhao X, Cheng S, Tan J, Cui W, Gao F, Lu W, Wang Y, Yang Y, Xia S, Wang S. Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial. Vaccine 2022:S0264-410X(22)00846-5. [PMID: 35810063 DOI: 10.1016/j.vaccine.2022.06.078] [Reference Citation Analysis]
6 Tsybalova LM, Stepanova LA, Ramsay ES, Vasin AV. Influenza B: Prospects for the Development of Cross-Protective Vaccines. Viruses 2022;14:1323. [PMID: 35746794 DOI: 10.3390/v14061323] [Reference Citation Analysis]
7 Carascal MB, Pavon RDN, Rivera WL. Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response. Front Immunol 2022;13:878943. [PMID: 35663997 DOI: 10.3389/fimmu.2022.878943] [Reference Citation Analysis]
8 Mintaev R, Glazkova D, Bogoslovskaya E, Shipulin G. Immunogenic epitope prediction to create a universal influenza vaccine. Heliyon 2022;8:e09364. [DOI: 10.1016/j.heliyon.2022.e09364] [Reference Citation Analysis]
9 Hamley IW. Peptides for Vaccine Development. ACS Appl Bio Mater 2022. [PMID: 35195008 DOI: 10.1021/acsabm.1c01238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lapuente D, Fuchs J, Willar J, Vieira Antão A, Eberlein V, Uhlig N, Issmail L, Schmidt A, Oltmanns F, Peter AS, Mueller-Schmucker S, Irrgang P, Fraedrich K, Cara A, Hoffmann M, Pöhlmann S, Ensser A, Pertl C, Willert T, Thirion C, Grunwald T, Überla K, Tenbusch M. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun 2021;12:6871. [PMID: 34836955 DOI: 10.1038/s41467-021-27063-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Li M, Guo P, Chen C, Feng H, Zhang W, Gu C, Wen G, Rao VB, Tao P. Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development. Front Immunol 2021;12:745625. [PMID: 34712234 DOI: 10.3389/fimmu.2021.745625] [Reference Citation Analysis]
12 Shahbari NAE, Gesser-Edelsburg A, Davidovitch N, Brammli-Greenberg S, Grifat R, Mesch GS. Factors associated with seasonal influenza and HPV vaccination uptake among different ethnic groups in Arab and Jewish society in Israel. Int J Equity Health 2021;20:201. [PMID: 34493294 DOI: 10.1186/s12939-021-01523-1] [Reference Citation Analysis]
13 Bull MB, Cohen CA, Leung NHL, Valkenburg SA. Universally Immune: How Infection Permissive Next Generation Influenza Vaccines May Affect Population Immunity and Viral Spread. Viruses 2021;13:1779. [PMID: 34578360 DOI: 10.3390/v13091779] [Reference Citation Analysis]
14 Giurgea LT, Cervantes-Medina A, Walters KA, Scherler K, Han A, Czajkowski LM, Baus HA, Hunsberger S, Klein SL, Kash JC, Taubenberger JK, Memoli MJ. Sex Differences in Influenza: The Challenge Study Experience. J Infect Dis 2021:jiab422. [PMID: 34423369 DOI: 10.1093/infdis/jiab422] [Reference Citation Analysis]
15 Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, Wijeyesinghe S, Soerens AG, Becker S, Thiede JM, Weyu E, O'Flanagan SD, Walter JA, Vu MN, Menachery VD, Bold TD, Vezys V, Jenkins MK, Langlois RA, Masopust D. Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. J Immunol 2021:ji2100421. [PMID: 34193597 DOI: 10.4049/jimmunol.2100421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
16 Kneitz C. Rheuma und Impfen. Aktuelle Rheumatologie 2021;46:214-20. [DOI: 10.1055/a-1286-2520] [Reference Citation Analysis]
17 Walling J, Zelnicek T, Johnson EJ, O'Neal KS. Shot of a lifetime: How pharmacists stay ahead of the season. J Am Pharm Assoc (2003) 2021;61:e214-7. [PMID: 33582029 DOI: 10.1016/j.japh.2021.01.015] [Reference Citation Analysis]
18 Schmidt A, Lapuente D. T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine. Viruses 2021;13:199. [PMID: 33525620 DOI: 10.3390/v13020199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
19 Mara K, Dai M, Brice AM, Alexander MR, Tribolet L, Layton DS, Bean AGD. Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production. Vaccines (Basel) 2021;9:59. [PMID: 33477334 DOI: 10.3390/vaccines9010059] [Reference Citation Analysis]
20 Lim HX, Lim J, Jazayeri SD, Poppema S, Poh CL. Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomed J 2021;44:18-30. [PMID: 33727051 DOI: 10.1016/j.bj.2020.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
21 Kneitz C, Müller-Ladner U. [Most important vaccinations in patients with rheumatological diseases and why]. Z Rheumatol 2020;79:855-64. [PMID: 32955610 DOI: 10.1007/s00393-020-00875-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Sun W, Luo T, Liu W, Li J. Progress in the Development of Universal Influenza Vaccines. Viruses 2020;12:E1033. [PMID: 32957468 DOI: 10.3390/v12091033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
23 Al-Azzam S, Ding Y, Liu J, Pandya P, Ting JP, Afshar S. Peptides to combat viral infectious diseases. Peptides 2020;134:170402. [PMID: 32889022 DOI: 10.1016/j.peptides.2020.170402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]